Britain and America have signed a significant bilateral deal that will preserve zero import taxes on British drug exports entering the US market.
Key Provisions of the Pact
As part of the deal, the UK has pledged to increase spending on drugs through the public health system. This pledge guarantees that duties on these key products will remain at nothing for a period of three years.
This deal comes after previous statements to significantly raise import taxes on patented pharmaceutical imports, with figures floated reaching 100%.
"This arrangement with the United Kingdom bolsters the international landscape for cutting-edge drugs and brings long-overdue fairness to U.S.–U.K. pharmaceutical trade," a statement noted.
Economic Impact
Medicines represent one of the Britain's largest export categories to the United States, which is easily the primary market for large British pharmaceutical firms.
Export figures indicate that in the one-year period to the end of last September, the UK shipped drugs valued at over eleven billion pounds to the US. This amount made up a significant portion of all goods exports in that timeframe.
"This agreement secures jobs, stimulates funding and sets the stage for the UK to become a global hub for medical research," the Business and Trade Secretary stated.
Detailed UK Commitments
The pact entails several key pledges from the British government:
- Price Threshold Increase: The UK will lift the cost ceiling at which it judges new therapies to be unaffordable by a quarter.
- Increased NHS Spending: There is a goal to raise total NHS spending on treatments from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Payback Limit: The percentage drug companies must refund to the NHS to stay within budget will be limited at fifteen percent. Last year, refunds topped twenty percent.
Broader Context
This agreement follows a protracted row between the pharmaceutical industry and the ministers over spending levels and NHS adoption.
These tensions were heightened by claims that American customers were paying a premium for the equivalent treatments than patients in the Britain and the EU.
Recently, several large drug company projects in the UK have been paused or scrapped, while multi-billion-dollar expansions have been announced toward American operations.
One official publicly accepted that the NHS needed to invest a greater share on medicines, noting that its spending on drugs had declined as a proportion of its total funding over the previous ten-year period.
